NCT03404661View on ClinicalTrials.gov

Optical and Biochemical Biomarkers in Early Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

346

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Pancreatic Cancer
Interventions
DRUG

Synthetic Human Secretin

Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER